Press Release
Source: BioCryst Pharmaceuticals, Inc.
On 8:04 pm EDT, Friday October 23, 2009
BIRMINGHAM, Ala., Oct. 23 /PRNewswire-FirstCall/ — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX - News) today announced that the U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention (CDC), has issued an emergency use authorization (EUA) for the investigational anti-viral drug intravenous (i.v.) peramivir in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.
Wow beeeeee this could be the train ride we need beeeeeeee have a great day beeeeee.
ReplyDeleteOh yea im in this one beeeeee its gonna be a long weekend without trading damn beeeeeeeee going crazy first night of no sleeping getting prepared for round 2........beeeeeeee
ReplyDelete